Denileukin diftitox
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stage IIIC Melanoma
Conditions
Stage IIIC Melanoma, Stage IV Melanoma
Trial Timeline
Jun 22, 2010 → Apr 7, 2015
NCT ID
NCT01127451About Denileukin diftitox
Denileukin diftitox is a phase 2 stage product being developed by Eisai for Stage IIIC Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01127451. Target conditions include Stage IIIC Melanoma, Stage IV Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Stage IIIC Melanoma were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01127451 | Phase 2 | Completed |
Competing Products
20 competing products in Stage IIIC Melanoma